Company intelligence / Profile preview

OncoImmune

Rockville, Maryland, United Statesoncimmune.com ↗

Ownership: Private
Development stage: Phase 3

Overview

OncoImmune’s lead product, CD24Fc, demonstrated efficacy in a Phase 3 trial for severe/critical COVID‑19 patients—showing a significant improvement over placebo—and was also studied up to pivotal trials for GVHD prevention. The company also initiated first-in-human studies of ONC‑392, a novel anti–CTLA‑4 antibody designed to improve safety and efficacy over existing checkpoint inhibitors.

Therapeutic areas: OncologyHematologyInfectious Diseases
Modalities: Recombinant fusion proteinsMonoclonal antibodiesProtein therapeuticsSmall molecules
Industry: Biotech

Drug pipeline

1 asset

CD24Fc

Phase 3

Indications: COVID-19, Graft versus host disease

Partnerships

Merck & Co.

Beyond the preview

Go deeper on OncoImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoImmune.

Explore the full profile